Protecting and commercialising precision-bred varieties: your IP options

England’s precision-breeding regime creates a new route to market for qualifying plants. But regulatory confirmation is only one part of commercialisation.

For plant breeders, agritech businesses and investors, the value of a new variety will depend partly on how its intellectual property is structured. The right strategy can protect both the technical innovation and the commercial variety.

The recent Beyond GM judgment has also created regulatory uncertainty. The High Court held that the decision to make the 2025 Regulations was unlawful because the Minister had misunderstood his powers over labelling and traceability. The regulatory regime remains in operation, but further change may follow.

These questions are no longer theoretical. The first precision bred confirmations for fruit plants have now been issued in England. They include eight gene-edited strawberry lines and a tomato that accumulates increased levels of pro-vitamin D3.

However, regulatory classification, food approval and commercial launch are separate stages. A precision bred confirmation does not itself authorise the resulting fruit for sale as food. Nor does it determine when a commercial product will reach the market.

Developers must coordinate precision bred confirmation with food authorisation, applicable variety and seed requirements, production arrangements and third-party IP rights. Against that background, early IP planning is essential.

Patents and PVRs: stronger together

Patents and plant variety rights protect different assets. Where both are available, they can provide valuable layers of protection.

Patents can protect the technical innovation. Plant variety rights, or PVRs, protect a defined commercial variety.

Consider a breeder that uses gene editing to introduce late-blight resistance into an established potato line. A patent might protect the editing method, the modified sequence or the technical basis of the resistance trait. A separate PVR could protect each distinct commercial potato variety carrying that trait.

Used together, they can provide flexible protection across a breeding programme. They may also make it harder for competitors to work around the protected innovation.

Obtaining a patent or PVR does not itself give the owner freedom to operate. Commercialisation may still require licences under third-party rights covering editing platforms, traits, germplasm or existing varieties.

What patents can protect

Patent protection may be available at several levels of a precision-breeding programme.

Potentially protectable inventions include editing tools and methods for introducing or identifying genetic changes. Modified sequences, molecular features and the mechanisms underlying valuable traits may also qualify.

Plant cells, plant material and technical uses of plants or harvested material may also be protectable. The position depends on the claims and the applicable exclusions.

The potential advantage is breadth. A patent directed to the technical basis of a resistance trait may cover several commercial varieties. In some cases, it may also cover more than one species.

This breadth can support licensing across several breeding programmes. It may also provide a commercial platform that outlasts any individual variety.

Patent protection comes with constraints. The invention must satisfy the requirements for novelty, inventive step, industrial applicability and sufficiency.

European and UK patent law exclude plant varieties and essentially biological processes for producing plants. In broad terms, these include conventional breeding processes based on crossing plants and selecting the resulting progeny.

A technical process that directly changes a plant’s genome may fall outside that exclusion. Gene editing can therefore support patent protection, although claim structure remains important. Patent claims concerning plants may be available where the technical teaching is not limited to a particular variety.

A patent application also requires public disclosure. Businesses should weigh the expected protection against the value of keeping some methods confidential.

What plant variety rights protect

PVRs protect a defined plant variety.

The variety must be new, distinct, uniform and stable. These are often called the DUS criteria. The variety must also have an acceptable denomination.

Precision bred status does not satisfy these requirements. Regulatory confirmation and PVR protection involve separate tests.

Returning to a potato plant example, PVR protection would not cover late-blight resistance as a technical concept. It could instead protect a defined potato variety that expresses the trait and satisfies the PVR requirements.

Another variety carrying the same resistance trait may require a separate PVR. However, the trait could still fall within the scope of a broader patent.

PVRs are commercially valuable because they focus on the production and sale of propagating material. In some circumstances, protection can also extend to harvested material.

Protection may also extend to essentially derived varieties. This can be important where a targeted edit is introduced into an existing protected variety. We will explore the scope and commercial effect of these provisions in a future article.

PVRs protect the variety, not the underlying technical concept. They are also subject to a breeder’s exemption.

This generally allows others to use the protected variety to develop new varieties. However, consent may still be needed to commercialise an essentially derived variety. Farm-saved seed rules also apply to certain species.

The EU system also treats PVR as a separate right for a defined variety. The Community Plant Variety Office administers the EU-wide system.

Managing PVR novelty

PVR novelty must also be managed carefully. A variety may lose novelty if propagating or harvested material has been sold or otherwise disposed of for commercial exploitation, with the breeder’s consent, before the applicable deadline.

For a UK application, the grace period is one year for disposals within the UK. It is four years for disposals elsewhere, or six years for trees and vines. The EU system applies equivalent periods by reference to disposals within and outside the EU.

Not every supply of plant material counts as commercial exploitation. Certain trial, evaluation and multiplication arrangements may be disregarded. The purpose and terms of the arrangement are important, so agreements should be reviewed before material changes hands.

Timing and public disclosure

Breeding managers, regulatory teams and IP advisers should manage these workstreams together, not in sequence. This is particularly important for collaborative breeding projects.

A marketing notice for precision bred confirmation includes details of genetic changes, techniques and analytical work. Much of this information may later appear on the public precision breeding register.

Some information can be withheld if it is commercially confidential. However, important information may still be published.

We recommend filing relevant patent applications before any public disclosure that could affect novelty. This may include regulatory publications, field-trial announcements, scientific papers and commercial presentations.

PVR timing also needs active management. Some sales and other disposals can start the applicable novelty period.

The project plan should cover patent filings, field trials and variety testing. It should also include PVR applications, regulatory notices and commercial launch.

Confidentiality and material-transfer terms should support each stage.

Building the right structure from the start

A strong portfolio may combine:

• patents for editing methods, traits and enabling platforms;
• PVRs for key commercial varieties;
• trade secrets for transformation, regeneration and production know-how;
• contracts governing germplasm, trials, multiplication and distribution; and
• trade marks for product and technology brands.

This approach creates licensing flexibility.

A platform patent may be licensed across several breeding programmes. A PVR licence can be limited by variety, crop, territory or commercial channel.

Ownership should be addressed at the outset. The organisation owning the editing platform may not own the background germplasm, the edited line or resulting variety. Ownership of edited material should never be assumed from ownership of the editing technology.

Collaboration agreements should address background IP and improvements. They should also cover edited lines, regulatory data, filing decisions and commercial rights.

The EU dimension

Overseas breeders should not assume that an English precision bred confirmation will support the same route in the EU. The two regimes are not equivalent.

The EU adopted Regulation (EU) 2026/1388 on 17 June 2026. It distinguishes between Category 1 and Category 2 plants obtained using new genomic techniques, or NGTs.

Verified Category 1 plants will broadly be treated like conventionally bred plants. Category 2 plants remain subject to a more extensive regulatory process.

Detailed implementing measures and guidance will be developed before the EU Regulation applies in July 2028. Developers should therefore keep the Category 1 criteria and verification process under review. Until then, existing EU GMO rules continue to apply to relevant NGT plants and products.

An English precision-bred plant should not be assumed to qualify as Category 1 in the EU. We will examine that comparison in a forthcoming article.

Commercial plans should identify where seed will be multiplied, crops grown and products sold. Regulatory approval, patents, PVRs, variety listing and seed certification are all territorial.

Where to start

The right strategy depends on the product, business model and target markets. Before committing to field trials or commercial launch, ask three questions.

What will create the commercial value?

Is it the editing platform, genetic change, trait or finished variety? The answer will shape which rights matter most.

What should be patented and what should remain confidential?

Would patent protection justify the disclosure required? Some processes may be better kept confidential, particularly where infringement would be difficult to detect.

Which third-party rights could block the route to market?

Relevant rights may include patents, PVRs, germplasm rights and contractual restrictions. Identifying them early can avoid expensive surprises before launch.

Precision breeding brings regulatory, patent and PVR strategy unusually close together. Early decisions on ownership, disclosure and target markets can shape the whole commercial pathway.

For breeders and agritech businesses, the aim is not simply to obtain as many rights as possible. It is to protect the assets that create value and secure the licences needed to reach the market.

If you are developing, licensing or investing in a precision-bred variety, we would be glad to discuss how these elements can be aligned from the outset.